Pay according to the disease, supplies reagent big impact

Recently, the General Office of Jiangsu Province promulgated the "Opinions on Further Deepening the Reform of Payment Methods of Basic Medical Insurance", explicitly requiring that the province should focus on the implementation of the payment by disease type and the expansion of disease-based diseases And the scope of medical institutions, by 2020, according to the kind of payment not less than 200 species.

According to the medical fees and charges as the highlight of Medicare policy, so far, many provinces have issued a notice to expand the scope of payment according to the disease, covering Guangxi, Zhejiang, Sichuan, Henan and other two thirds of the country.This change marks China's medical reform is taking a substantial step forward.

Payments by type of disease is the treatment of a prescribed disease, the hospital can only be charged to patients a fixed standard cost; if the hospital in the treatment cost more than the standard, beyond the part of the hospital itself; if you do not meet this standard, the savings are owned by the hospital, Can be used primarily for medical staff incentives.Hospital from the efficiency point of view, the natural way to find ways to cure the disease on the basis of substantial cost savings.

From the diagnosis to the entire process of treatment, covering the inspection, inspection and other medical and pharmaceutical companies products and services in the disease-based pricing policy, the hospital will be right medical instruments Product bidding prices to suppress and limit their use, reduce the consumption ratio, the previous major inspections, prescriptions, overuse of consumables and other acts may be reduced.

Imaging diagnostics such as CT, MRI, ultrasound imaging and endoscopic imaging are the most important diagnostic devices in major examinations. While reducing the number of large-scale medical examinations, the purchase and maintenance costs of related instruments will inevitably decrease, leading to medical equipment enterprise Profit decline.At the same time, the diagnosis and treatment will also use a large number of medical supplies, the treatment process specifications, the use of these supplies will be reduced accordingly.

According to one of the top three in Beijing hospital Hospitalized patients revealed that the hospital has been implemented in accordance with the type of billing, the hospital for the control of costs, right drug , The use of consumables are strictly controlled.For example, to replace the gauze, according to the past, usually a change every day, but this hospitalization, not for a few days for a patient feel very worried, but the doctor said it does not matter, there will be no infection, Let the patient feel relieved finally did not have an accident, the treatment process is very smooth.

At the same time, the amount of medication during hospitalization is also small.Patients want to use some two drugs, doctors think it is not necessary, but if you really do not trust, can be outside the community pharmacy Take medicine.

It can be seen that, according to the type of disease charges to ensure the medical effect under the premise, but also really reduce the burden on patients' costs, the doctor-patient relationship will also be improved.

At present, in the provincial selection of disease-specific diseases, the National Development and Reform Commission provided 320 kinds of diseases for the implementation of the use of all over the city public hospital comprehensive reform pilot areas by the end of 2017 the implementation of the disease-based diseases not less than 100 .

At present, Zhangzhou City, which is the most endemic area to be introduced, will launch more than 200 kinds of diseases this year. In addition, Jiangsu Province and Guangdong Province have also clearly pointed out that more than 200 kinds of diseases will be introduced within two years.

The increase in the number of diseases will undoubtedly cause the hospital to significantly reduce the cost of treatment while the profit margins of companies such as pharmaceuticals, medical consumables and diagnostic reagents will be greatly reduced compared with previous years, and this part of the missing space will now be produced Manufacturers, distributors, home users, end users shared, the industry's weak competitiveness of manufacturers, businesses or will be subjected to the pressure of being shuffled.